BIO.B Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Rad Laboratories Inc (BIO.B) is not a strong buy for a beginner, long-term investor at this time. The lack of clear positive catalysts, recent downgrades by analysts, and weak financial performance overshadow the slight technical positivity and hedge fund interest. Holding the stock or waiting for better entry points is recommended.
The MACD histogram is positive at 2.428, indicating a bullish trend, but it is contracting. RSI is neutral at 65.675, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its resistance level of 294.393, with support at 273.666. The technical indicators do not provide a clear buy signal.
Hedge funds are significantly increasing their positions, with a 333305.80% increase in buying activity over the last quarter.
Recent analyst downgrades highlight concerns about the company's process chromatography business and uncertainties in the China diagnostics space. Financial performance in Q4 2025 showed a significant drop in net income (-200.59% YoY) and EPS (-204.22% YoY), along with declining gross margins.
In Q4 2025, revenue increased by 3.85% YoY to $693.2M, but net income dropped by -200.59% YoY to $720M. EPS fell by -204.22% YoY to 26.65, and gross margin decreased by 2.89% YoY to 49.74%. The financial performance indicates challenges in profitability and margin management.
Analysts have recently downgraded the stock. Citi downgraded it to Neutral with a price target of $300 (down from $375), citing concerns about the process chromatography business and China diagnostics space. Wells Fargo and UBS also lowered their price targets, highlighting weak guidance and margin issues.
